Hepatitis C Global Clinical Trials Review, H2, 2017

Date: September 15, 2017
Pages: 1564
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H4EAF1D8449EN
Leaflet:

Download PDF Leaflet

Hepatitis C Global Clinical Trials Review, H2, 2017
Hepatitis C Global Clinical Trials Review, H2, 2017

SUMMARY

GlobalData's clinical trial report, “Hepatitis C Global Clinical Trials Review, H2, 2017' provides an overview of Hepatitis C clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis C. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

REASONS TO BUY
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Hepatitis C to Infectious Disease Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Hepatitis C Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Hepatitis C
Aug 17, 2017: Gilead Receives Approval in Canada for VOSEVI (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection
Aug 16, 2017: The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir
Aug 15, 2017: Cocrystal Announces Positive Data from the Successful Completion of Phase 1a/1b Trial of the Non-Nucleoside Polymerase Inhibitor CC-31244 for the Treatment of Chronic Hepatitis C Infection
Clinical Trial Profile Snapshots
Appendix 1562
Abbreviations 1562
Definitions 1562
Research Methodology 1563
Secondary Research 1563
About GlobalData 1564
Contact Us 1564
Source 1564

LIST OF TABLES

Hepatitis C Therapeutics, Global, Clinical Trials by Region, 2017
Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017
Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017
Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017
Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries, 2017
Hepatitis C Therapeutics Clinical Trials, North America, Top Countries, 2017
Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017
Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017
Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017
Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017
Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017
Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017
Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017
Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017
Hepatitis C Therapeutics, Global, Clinical Trials by Phase, 2017
Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase 2017
Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017
Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017

LIST OF FIGURES

Hepatitis C Therapeutics, Global, Clinical Trials by Region (%), 2017
Hepatitis C Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017
Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017
Hepatitis C Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017
Hepatitis C Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017
Hepatitis C Therapeutics Clinical Trials, North America, Top Countries (%), 2017
Hepatitis C Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017
Hepatitis C Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017
Proportion of Hepatitis C to Infectious Disease Clinical Trials, G7 Countries (%), 2017
Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Phase, 2017
Hepatitis C Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017
Proportion of Hepatitis C to Infectious Disease Clinical Trials, E7 Countries (%), 2017
Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Phase, 2017
Hepatitis C Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017
Hepatitis C Therapeutics, Global, Clinical Trials by Phase (%), 2017
Hepatitis C Therapeutics, Global, Clinical Trials In Progress by Phase, 2017
Hepatitis C Therapeutics, Global, Clinical Trials by Trial Status, 2017
Hepatitis C Therapeutics Clinical Trials, Global, by End Point Status, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Hepatitis C Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017
Hepatitis C Therapeutics Clinical Trials, Global, Key Sponsors, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017
Hepatitis C Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017
GlobalData Methodology 1563

COMPANIES MENTIONED

Merck & Co Inc
F. Hoffmann-La Roche Ltd
Gilead Sciences Inc
Johnson & Johnson
AbbVie Inc
Bristol-Myers Squibb Company
Vertex Pharmaceuticals Inc
C. H. Boehringer Sohn AG & Co KG
Novartis AG
GlaxoSmithKline Plc
Skip to top


Hepatitis B Global Clinical Trials Review, H2, 2017 US$ 2,500.00 Sep, 2017 · 867 pages

Ask Your Question

Hepatitis C Global Clinical Trials Review, H2, 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: